• Vidyo

  Participated · Equity · Jul 2014

  Vidyo offers the VidyoWorks software platform and APIs that embed real-time video, audio and content communication into clinical workflows and consumer-facing applications. The platform includes a FIPS 140-2 certified crypto-kernel providing HIPAA-compliant encryption and is used by enterprise customers, service providers, and ecosystem partners. Vidyo’s technology powers telehealth applications for more than 40% of the top 100 Integrated Delivery Networks in the U.S. and is integrated with major EHR systems and a wide set of healthcare workflow tools. The company reports millions of users connecting daily and holds over 110 patents. Vidyo plans to use the latest funding to accelerate growth in vertical markets and expand its healthcare deployments. Vidyo offers the VidyoWorks platform and APIs, leveraging Scalable Video Coding (SVC) and the patented VidyoRouter to deliver scalable video conferencing and integration into workflows and devices. The company supplies video infrastructure and products such as VidyoRoom systems and personal telepresence for markets including banking, healthcare, government and enterprise. Vidyo reports deployments with capacity exceeding hundreds of millions of minutes per year in some networks and more than 1,200 VidyoRoom systems in others. It holds more than 60 patents issued and patents pending across 65 patent families. Vidyo positions its technology to enable integration of visual communications into electronic medical records and new connected devices, targeting broader adoption as the Internet of Things expands. The company will use newly raised funds for sales and market development to broaden adoption of the VidyoWorks platform. Vidyo develops software-based video conferencing that lets customers use existing room systems (Cisco, Polycom, Lifesize, H.323/SIP), Microsoft Lync clients, and mobile devices. Its approach targets lower-cost alternatives to hardware-based incumbents and supports virtualized deployments on off-the-shelf equipment. The company reported year-over-year billings growth of 68% in 2012, with sales up 77% in both healthcare and education verticals. Vidyo has more than 250 employees across 13 global offices and holds 26 issued patents with 56 pending. With the new funding, the company plans to continue growing its engineering team and expand worldwide, and it recently struck a distribution deal with education consortium Internet2. Vidyo builds video conferencing software that uses H.264 Scalable Video Coding (SVC) to deliver high-quality calls even on constrained mobile networks. It sells some conferencing equipment directly to enterprises and has a large and growing OEM licensing business with partners including Google, Ricoh and Hitachi. The company announced a strategic investment from Juniper Networks via the Junos Innovation Fund; terms of that investment were not disclosed. The Juniper investment could foreshadow a closer partnership or a possible acquisition and potential integration of Vidyo’s technology into Juniper networking equipment. Vidyo is headquartered in Hackensack, New Jersey, operates 12 other offices and has about 225 employees. Since its founding in 2005 the company has raised about $100 million in total funding. Vidyo pioneers personal telepresence with a software-based communication and collaboration platform that spans immersive rooms, desktops, tablets and smartphones. Its VidyoRouter is built on a patented Adaptive Video Layering architecture that leverages H.264 Scalable Video Coding to eliminate the MCU and provide error resiliency, low latency and rate matching over Internet, LTE, 3G and 4G networks. The platform includes gateways that interoperate with H.323 and SIP endpoints and supports cloud-based broadcast solutions. Vidyo holds 9 awarded patents and has 27 patents pending, and has received industry recognition including Best of Interop, Frost & Sullivan and Wall Street Journal honors. The company plans to use the new funding to expand sales and marketing globally to address demand for flexible, scalable telepresence across devices. Since its founding in 2005, Vidyo has raised $97 million in total capital.

• Netsocket

  Participated · Series B · Apr 2013

  NetSocket provides network service assurance solutions designed to deliver a trouble-free unified communications experience for enterprises and service providers. The company’s Cloud Experience Manager (CEM) optimizes Microsoft Lync UC service management and user experience. NetSocket plans to apply its service assurance, routing, and policy-control software into virtualized networks and Software Defined Networking (SDN) architectures. The company announced a new product targeted at the growing SDN market, with a product announcement and launch planned for this summer. NetSocket is based in Plano, Texas, and aims to use recent funding to accelerate that SDN-focused solution launch. The company highlights an expanded collaboration with Microsoft as evidence of traction in its UC offering.

• Alder Biopharmaceuticals

  Participated · Series D · Apr 2012

  Alder BioPharmaceuticals is a Bothell, Washington-based developer and manufacturer of novel antibody therapeutics targeting cancer, pain, cardiovascular and autoimmune and inflammatory diseases. Its pipeline includes ALD403, an investigational monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP) to prevent migraine attacks, and ALD518, an investigational monoclonal antibody to the pro-inflammatory cytokine IL-6. The company intends to use the Series D funding to advance ALD403 into the clinic this quarter and to support ongoing Phase 2 studies of ALD518 in cancer-related indications. Alder is led by president and CEO Randall Schatzman, Ph.D. The company closed a $38M Series D financing to support these clinical development plans. Alder Biopharmaceuticals develops antibody-based drugs targeting inflammation and autoimmune disease, with a lead candidate ALD518 in clinical trials for rheumatoid arthritis and cancer. The company uses a yeast-based manufacturing platform to produce full-length functioning antibodies at industrial scale, which it says is faster and cheaper than mammalian-cell methods. Alder claims yeast production can shorten development timelines from years to months and avoid expensive patent licenses tied to traditional techniques. That platform is intended to allow evaluation of a wider range of antibody candidates. Financially, the company completed a third funding round that raised $40 million. The articles do not disclose revenue or other operating metrics.

• Luxtera

  Participated · Series C · Feb 2012

  Luxtera developed a Silicon Photonics technology platform that allows construction of complex optical systems in production CMOS processes, the same processes used for building VLSI circuits. The company is led by president and CEO Greg Young and was founded in 2001. It closed a $21.7M Series C to accelerate adoption of its Silicon CMOS Photonics. Luxtera intends to use the funding to pursue design-win opportunities and increase market adoption of its technology. The company has added Martin Colombatto to its board and is actively hiring to support growth and commercialization efforts. Luxtera is a Carlsbad-based Caltech spinoff that develops optical interconnects and optoelectronic products. Its product lineup includes an optoelectronic cable capable of data transmission up to 40 Gbps. The company is working under contracts with Sun Microsystems and DARPA to develop chip-to-chip optical interconnects using CMOS processes. According to the PricewaterhouseCoopers/NVCA MoneyTree report, Luxtera raised $26.75M in another venture round. No further details on the funding participants or terms for this round were disclosed in the report. The firm has previously raised three rounds of capital from investors including August Capital, ITU Ventures, New Enterprise Associates, Sevin Rosen Funds, and Zone Ventures. Luxtera is developing semiconductors that combine optical components with CMOS electronics. The company aims to commercialize these integrated photonic-CMOS chips for high-volume applications. It closed a $22M Series C to accelerate its product launch and scale to volume production. The funding round was intended to move the company from development toward commercial manufacturing. Luxtera is based in Carlsbad. The announcement was reported on March 16, 2006.

• Metabolon

  Participated · Series D · Aug 2011

  Metabolon provides metabolomics and lipidomics solutions that support life‑science research, diagnostics, therapeutic development, and precision medicine applications. Its platform includes a Global Discovery Panel enabled by a proprietary metabolomics reference library and scalable, customizable multiomics offerings that span discovery through clinical trials and product life‑cycle management. The company cites more than 20 years of activity, 10,000+ projects, and 3,000+ publications, and holds ISO 9001:2015, CLIA, and CAP certifications. Led by CEO Rohan (Ro) Hastie and based in Morrisville, NC, Metabolon positions itself as a global leader in metabolomics. The company intends to use recent financing to enhance growth initiatives, expand research and development, and further develop its metabolomics platform. It also plans to support global expansion, market penetration initiatives, and strategic partnerships. Metabolon is a Morrisville, NC-based provider of scalable, customizable metabolomics and lipidomics solutions supporting customer needs from discovery through clinical trials and product life-cycle management. Led by CEO Rohan (Ro) Hastie, the company serves research, diagnostic, therapeutic development, and precision medicine applications. Its offerings include a Global Discovery Panel enabled by a proprietary metabolomics reference library and scientific, technology, and bioinformatics techniques developed over more than 20 years. Metabolon reports completing 10,000+ projects and being cited in over 3,000 publications, and holds ISO 9001:2015 and CLIA certifications. The company recently raised $25M and intends to use the funds to accelerate commercialization activities and continue advancing its R&D roadmap. Metabolon provides scalable, customizable metabolomics solutions from discovery through clinical trials and product life-cycle management using its Precision Metabolomics™ Platform and proprietary reference library. Over more than 20 years the company has completed 10,000+ projects and contributed to 2,000+ publications, and holds ISO 9001:2015 and CLIA certifications. Its technology deciphers thousands of discrete chemical signals to reveal biological pathways and phenotype-level insights that other 'omics cannot. The company recently closed a $72 million combined debt and equity financing to support growth. Management says the incremental funding will accelerate growth, expand the client base, and fund R&D programs in machine learning for novel biomarker discovery and to expand its precision medicine platform. Metabolon also announced the appointment of Robert A. Cascella to its board alongside independent members Todd Schermerhorn and Jan Lundberg. Metabolon develops proprietary metabolomics platforms and informatics to deliver biomarker discoveries, diagnostic tests, and precision medicine products. The company plans to use the financing proceeds to further develop and commercialize its pipeline of precision medicine offerings based on its metabolomics technology. Metabolon serves clients across pharmaceutical, biotechnology, consumer products, agriculture, nutrition, academic, and government sectors. It has conducted more than 5,000 independent and collaborative studies and has over 600 peer-reviewed publications. Founded in 2000 and led by president and CEO John Ryals, Ph.D., the company is based in Research Triangle Park, N.C. Financially, Metabolon has raised approximately $80M to date and closed a new financing to support its commercialization efforts. Metabolon is a metabolomics firm in the precision medicine space that develops phenotyping technology to determine individual drug metabolism and response. Its core product uses metabolomics profiling to inform drug-response and precision-treatment decisions. The company announced a collaboration last year with Human Longevity Inc. According to a Wall Street Journal report, Metabolon generated about $25 million in revenue last year. It has been backed by roughly $50 million in private funding from investors including Aurora Funds Inc., Fletcher Spaght Ventures LP, Syngenta Ventures, Sevin Rosen Funds, Harris & Harris Group Inc., and Keating Capital Inc. Company representatives had not provided details on how the new funding will be used.

No current team members are available.